{"transactions":[{"id":1783008,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-12T20:07:09.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":48000,"derivative":{"exercise_price":0.84,"expiration_date":"2033-09-08","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001610717-23-000275","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000275/form4.xml","form_type":"4"}},{"id":1947234,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-17T20:10:54.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":78750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":78750,"derivative":{"exercise_price":1.34,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":78750},"source":{"system":"sec-edgar","filing":"0001567619-23-005254","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761923005254/doc1.xml","form_type":"4"}},{"id":2209239,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-11T20:15:13.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":52500,"derivative":{"exercise_price":1.41,"expiration_date":"2032-07-07","underlying":"Common Stock","underlying_shares":52500},"source":{"system":"sec-edgar","filing":"0001567619-22-013869","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922013869/doc1.xml","form_type":"4"}},{"id":2408519,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-08T21:07:58.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":26250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the Option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such vesting date."}],"balance_after":26250,"derivative":{"exercise_price":3.06,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":26250},"source":{"system":"sec-edgar","filing":"0001567619-22-002890","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922002890/doc1.xml","form_type":"4"}},{"id":2408518,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-08T21:07:58.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":105000,"derivative":{"exercise_price":3.06,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001567619-22-002890","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922002890/doc1.xml","form_type":"4"}},{"id":2958794,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-04T01:04:13.000Z","date":"2020-12-01","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from December 1, 2020 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":200000,"derivative":{"exercise_price":16.18,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001567619-20-020623","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920020623/doc1.xml","form_type":"4"}},{"id":3003077,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Series B-2 Preferred Stock","published_at":"2020-10-20T20:56:39.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":726,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":726},"source":{"system":"sec-edgar","filing":"0001567619-20-018004","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018004/doc1.xml","form_type":"4"}},{"id":3003076,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Series B-1 Preferred Stock","published_at":"2020-10-20T20:56:39.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":1697,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1697},"source":{"system":"sec-edgar","filing":"0001567619-20-018004","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018004/doc1.xml","form_type":"4"}},{"id":3003075,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Series A Preferred Stock","published_at":"2020-10-20T20:56:39.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":6835,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6835},"source":{"system":"sec-edgar","filing":"0001567619-20-018004","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018004/doc1.xml","form_type":"4"}},{"id":3003074,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-10-20T20:56:39.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":726,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010."}],"balance_after":9258,"source":{"system":"sec-edgar","filing":"0001567619-20-018004","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018004/doc1.xml","form_type":"4"}},{"id":3003073,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-10-20T20:56:39.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":1697,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010."}],"balance_after":8532,"source":{"system":"sec-edgar","filing":"0001567619-20-018004","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018004/doc1.xml","form_type":"4"}},{"id":3003072,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-10-20T20:56:39.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":6835,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010."}],"balance_after":6835,"source":{"system":"sec-edgar","filing":"0001567619-20-018004","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018004/doc1.xml","form_type":"4"}}]}